DiGA Pricing and Reimbursement: How the German System Works
DiGA reimbursement is not a one-way revenue escalator. How prices are set, why they decline, and what startups should model before committing to the German path.
Category
Funding, Business Models & Reimbursement
45 in-depth guides in this cluster
Lessons from DiGA Rejections: Why Apps Fail and How to Avoid It
DiGA rejections are not random. The patterns are clinical evidence, economic benefit, interoperability, and data protection. An honest reality check for startups.
DiGA-Like Frameworks Across Europe: Belgium, France, Digital Pathways
DiGA European digital health frameworks compared: France PECAN, Belgium mHealth pyramid, and other national routes for CE-marked SaMD founders.
The European Health Data Space (EHDS): What It Means for MedTech
European Health Data Space EHDS MedTech impact: primary and secondary data use, manufacturer obligations, and how MDR PMS and PMCF connect to the EHDS.
Funding a MedTech Startup: The Complete Guide to Financing Regulated Products
Funding a MedTech startup is not the same as funding SaaS. The cost of regulation, the time to revenue, and the investor expectations all differ. Here is the complete guide.
Why MedTech Startups Need More Capital Than SaaS, And How to Plan for It
MedTech startups need 3-10x more capital than SaaS to reach revenue. The difference is not technical complexity, it is the 18-24 month regulatory path. Here is the math.
Pre-Seed and Seed Funding for MedTech: What Investors Expect Before CE Marking
Raising pre-seed and seed for a MedTech startup is harder than SaaS because investors want evidence of the regulatory path. Here is what they actually want to see.
Series A for MedTech Startups: What You Need to Show Beyond Product-Market Fit
Series A in MedTech needs more than PMF. Investors want a regulatory milestone, clinical evidence plan, and path to revenue. Here is what to show.
Venture Capital for MedTech in Europe: The Investor Landscape in 2026
European MedTech VC has matured but still lags US deal sizes. Here is the 2026 investor landscape and what MedTech founders should expect at each round.
Angel Investors for MedTech: Finding Early-Stage Backers
Where MedTech angel investors concentrate, what they fund, and why regulatory readiness is the filter that decides who writes the first check.
Non-Dilutive Funding for MedTech Startups: Grants, Loans, and Public Programs
Non-dilutive funding can carry a MedTech startup through the regulatory valley without giving up equity. Here is the landscape across Europe in 2026.
EU Funding for MedTech Startups: Horizon Europe, EIC Accelerator, and Beyond
Horizon Europe, EIC Accelerator, EIT Health, the EU funding stack for MedTech is complex. Here is the overview at general framing.
Austrian Funding for MedTech Startups: AWS, FFG, and Regional Programs
Austria has one of Europe's strongest MedTech funding ecosystems. Here is how AWS, FFG, and regional programs work for startups, with the honest caveats on current terms.
German Funding for MedTech Startups: EXIST, BMBF, State Programs
EXIST, BMBF, and state-level funding for German MedTech startups, eligibility, regulatory milestones tied to disbursement, and what to apply for when.
Swiss Funding for MedTech Startups: Innosuisse and Cantonal Programs
Innosuisse, cantonal programmes, and the third-country reality of Switzerland under MDR, how Swiss MedTech startups fund the extra regulatory burden.
EIC Accelerator for MedTech: How to Write a Winning Application
The EIC Accelerator is the largest non-dilutive grant programme for European MedTech. Here is how to write a winning application at general framing.
How to Pitch a MedTech Startup: The Regulatory Slide Decoded
Every MedTech pitch deck needs a regulatory slide. Here is what MedTech investors actually want to see on it, and what kills the round.
MedTech Investor Due Diligence: Regulatory and QMS
What MedTech investors check in regulatory and QMS due diligence: red flags that kill rounds, the evidence pack to assemble, who gets interrogated.
Strategic Investors in MedTech: When a Corporate VC Makes Sense
When strategic investors and corporate VCs make sense for MedTech startups, what they bring beyond money, and the alignment risks to weigh first.
Revenue Before CE Mark: Legal Ways to Generate Income
Legal ways to generate revenue before CE mark: services, custom-made devices, R&D contracts, and investigational use, with MDR citations.
Crowdfunding for Medical Devices: Legal and Regulatory Considerations
Crowdfunding medical devices legally: MDR Article 7 promotional traps, Article 5 placement rules, pre-orders, and equity crowdfunding alternatives.
MedTech Startup Budget Planning: What You Will Actually Spend on Regulatory
A MedTech startup budget must allocate for regulatory work from day one. Here is the line-by-line budget template and the common traps founders fall into.
The True Cost of CE Marking: A Transparent Breakdown for Investors and Founders
The real cost of CE marking a medical device in 2026, broken down by category and class. Useful for investor pitches and founder sanity.
Burn Rate Management for MedTech Startups: Surviving the Regulatory Timeline
MedTech burn rate is determined by regulatory milestones, not feature releases. Here is how to manage burn rate so you reach CE marking without a gap round.
Financial Modeling for MedTech Startups Under MDR
How to build a defensible financial model for a MedTech startup when MDR timelines, notified body queues, and audit cycles drive every assumption.
Reimbursement Strategy for Medical Devices in Europe
A startup guide to reimbursement strategy for medical devices in Europe: why CE mark is not enough, how HTA works, and how to sequence markets.
How Health Insurance Reimbursement Works in Europe: The MedTech Founder's Primer
Health insurance reimbursement in Europe is country-specific, slow, and the gating factor for revenue. Here is the founder's primer.
German Reimbursement for Medical Devices: GKV, NUB, and DRG Explained
Germany is Europe's largest medical device market. Here is the GKV, NUB, and DRG reimbursement framework for MedTech startups at general framing.
French Reimbursement: LPPR and CNEDIMTS Evaluation
How French reimbursement works for medical devices: LPPR listing, CNEDIMTS evaluation, evidence demands, timelines, and common rejection reasons.
UK Reimbursement for Medical Devices: NHS, NICE, and HTA
UK reimbursement medical devices NHS NICE: how NHS procurement, NICE appraisal and UKCA marking fit together, and how EU startups should sequence entry.
Austrian Reimbursement for Medical Devices: The Payer System
How Austrian social insurance, hospital budgets, and the LKF system reimburse medical devices, and what MedTech founders need to prepare.
Health Economic Evaluation for Medical Devices: A Founder's Primer
What health economic evaluation actually is for MedTech startups, cost-effectiveness, budget impact, QALYs, and when to commission a study.
HTA Submissions for Medical Devices: How to Prepare Evidence That Gets Approval
Health Technology Assessment bodies decide whether a device deserves public coverage. Here is how to prepare the evidence submission at general framing.
Coverage with Evidence Development: Reimbursement While You Generate Evidence
How coverage with evidence development (CED) lets MedTech startups get reimbursed while generating the clinical data payers demand.
Value-Based Pricing for Medical Devices: Linking Price to Outcomes
Value-based pricing medical devices: how outcome-based contracting works, evidence you need, risks, and how MDR PMS becomes your data backbone.
Reimbursement for Digital Health in Europe: Beyond DiGA
Reimbursement digital health Europe beyond DiGA: Germany, France PECAN, Belgium m-Health. Country-by-country evidence, MDR overlap, dual-pathway strategy.
How Reimbursement Strategy Affects Your Regulatory Strategy
Reimbursement strategy regulatory strategy MedTech: plan both together. Evidence stack design, Article 61, classification and HTA, startup playbook.
MedTech Startup Exit Strategy: M&A, IPO, and Strategic Partnerships
MedTech exits look different from SaaS exits. Here is the M&A, IPO, and partnership reality for MedTech startups in Europe.
MedTech M&A: How Acquirers Evaluate Regulatory Assets
How MedTech acquirers diligence regulatory assets under MDR, CE certificate transferability, QMS maturity, CER currency, and PMS continuity.
Licensing MedTech Technology: The Partnership Approach
How to license MedTech technology to established companies under MDR, who becomes the manufacturer, royalty structures, IP carve-outs, and regulatory hand-over.
MedTech Startup Valuation: How Regulatory Milestones Drive Enterprise Value
MedTech valuations are anchored to regulatory milestones more than to revenue. Here is how each milestone moves the value.
Cash Flow Management for MedTech Startups
Cash flow management for MedTech startups, timing regulatory costs against revenue, managing the cash trough, and surviving the MDR Article 52 assessment cycle.
How to Extend Your Runway in Regulated MedTech Development
Extend runway in MedTech without breaking MDR. What costs you can defer, what must stay, and how to stretch capital without losing compliance.
MedTech Startup Funding Checklist: Pre-Seed to Series A in 2027
The MedTech startup funding checklist for 2027. Regulatory deliverables mapped to each round from pre-seed to Series A, with investor red flags.
Regulatory Costs as Cost of Goods Sold
Treat regulatory costs as COGS, not one-off CapEx. Why MDR Article 10 obligations belong in MedTech unit economics and how to model them honestly.